Synergy Pharmaceuticals (SGYP) signs an Asset Purchase Agreement with Bristol-Myers Squibb (BMY)...

|About: Synergy Pharmaceuticals, Inc. (SGYP)|By:, SA News Editor

Synergy Pharmaceuticals (SGYP) signs an Asset Purchase Agreement with Bristol-Myers Squibb (BMY) to acquire the assets related to FV-100, an oral nucleoside analogue currently being developed for the treatment of shingles, a severe, painful skin rash caused by chickenpox.